Fabrazyme

Rocky Path

Biotech

Protalix eyes 2nd try at Fabry med in 2H22

Protalix intends to resubmit its once-rejected Fabry disease drug to the FDA in the second half of this year thanks to new phase 3 data.

Kyle LaHucik Mar 18, 2022 9:22am

FDA Building 2

Avrobio plans Fabrazyme trial after FDA changes path to market

May 3, 2021 8:55am

Scott Gottlieb

Change of tack? FDA backpedals on Amicus NDA, extra safety tests

Jul 11, 2017 7:22am